Analogs of luteinizing Hormone-Releasing hormone in the treatment of endometriosis

Jörg B. Engel, Hans R. Tinneberg, Norman L Block, Eniko Berkes, Andrew V Schally

Research output: Contribution to journalArticle

Abstract

Agonists of luteinizing hormone-releasing hormone (LHRH) induce a reversible hypoestrogenic state through the down-regulation of LHRH receptors and desensitization of the pituitary. Since endometrial implants are estrogen sensitive, LHRH agonists have frequently been used for medical treatment of endometriosis. Nowadays, LHRH agonists can be considered in general as a second-line medical treatment for endometriosis-related symptoms, as oral therapy with dienogest is as effective and has fewer side effects. However, therapy with LHRH agonists for 3-6 months prior to in vitro fertilization remains the treatment of choice in patients with endometriosis, as it significantly increases pregnancy rates. LHRH agonists are used prior to surgery and as an adjuvant after an operation to prevent recurrence or prolong disease-free intervals. Adverse effects of LHRH agonists are due to hypoestrogenism and include hot flushes, vaginal dryness, loss of libido, sleep disturbances and a diminished bone density which limits the duration of their administration to 6 months. For long-term treatment, add-back of estrogen and/or progestin,/or progestin only with or without bisphosphonates, can be used, but existing studies only cover a 12-month period of treatment. LHRH antagonists competitively block the pituitary receptors for LHRH. Consequently, a partial pharmacological hypophysectomy with a reduction of the estrogen levels to a desired level is possible if LHRH antagonists are adequately dosed. As endometriotic implants require relatively high levels of estrogen, partially lower plasma levels of estrogens are sufficient to prevent the loss of bone density. A long-term treatment without add-back therapy is also possible.

Original languageEnglish (US)
Pages (from-to)19-26
Number of pages8
JournalJournal of Endometriosis
Volume7
Issue number1
DOIs
StatePublished - Apr 10 2015

Fingerprint

Endometriosis
Gonadotropin-Releasing Hormone
Estrogens
Hormone Antagonists
dienogest
Therapeutics
Progestins
Bone Density
LHRH Receptors
Libido
Hypophysectomy
Diphosphonates
Pregnancy Rate
Fertilization in Vitro
Sleep
Down-Regulation
Pharmacology
Recurrence

Keywords

  • Endometriosis
  • LHRH agonist
  • LHRH antagonist
  • Medical treatment

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Analogs of luteinizing Hormone-Releasing hormone in the treatment of endometriosis. / Engel, Jörg B.; Tinneberg, Hans R.; Block, Norman L; Berkes, Eniko; Schally, Andrew V.

In: Journal of Endometriosis, Vol. 7, No. 1, 10.04.2015, p. 19-26.

Research output: Contribution to journalArticle

Engel, Jörg B. ; Tinneberg, Hans R. ; Block, Norman L ; Berkes, Eniko ; Schally, Andrew V. / Analogs of luteinizing Hormone-Releasing hormone in the treatment of endometriosis. In: Journal of Endometriosis. 2015 ; Vol. 7, No. 1. pp. 19-26.
@article{cd82c3885a0842efbefa8182c77b4af1,
title = "Analogs of luteinizing Hormone-Releasing hormone in the treatment of endometriosis",
abstract = "Agonists of luteinizing hormone-releasing hormone (LHRH) induce a reversible hypoestrogenic state through the down-regulation of LHRH receptors and desensitization of the pituitary. Since endometrial implants are estrogen sensitive, LHRH agonists have frequently been used for medical treatment of endometriosis. Nowadays, LHRH agonists can be considered in general as a second-line medical treatment for endometriosis-related symptoms, as oral therapy with dienogest is as effective and has fewer side effects. However, therapy with LHRH agonists for 3-6 months prior to in vitro fertilization remains the treatment of choice in patients with endometriosis, as it significantly increases pregnancy rates. LHRH agonists are used prior to surgery and as an adjuvant after an operation to prevent recurrence or prolong disease-free intervals. Adverse effects of LHRH agonists are due to hypoestrogenism and include hot flushes, vaginal dryness, loss of libido, sleep disturbances and a diminished bone density which limits the duration of their administration to 6 months. For long-term treatment, add-back of estrogen and/or progestin,/or progestin only with or without bisphosphonates, can be used, but existing studies only cover a 12-month period of treatment. LHRH antagonists competitively block the pituitary receptors for LHRH. Consequently, a partial pharmacological hypophysectomy with a reduction of the estrogen levels to a desired level is possible if LHRH antagonists are adequately dosed. As endometriotic implants require relatively high levels of estrogen, partially lower plasma levels of estrogens are sufficient to prevent the loss of bone density. A long-term treatment without add-back therapy is also possible.",
keywords = "Endometriosis, LHRH agonist, LHRH antagonist, Medical treatment",
author = "Engel, {J{\"o}rg B.} and Tinneberg, {Hans R.} and Block, {Norman L} and Eniko Berkes and Schally, {Andrew V}",
year = "2015",
month = "4",
day = "10",
doi = "10.5301/je.5000208",
language = "English (US)",
volume = "7",
pages = "19--26",
journal = "Journal of Endometriosis",
issn = "2035-9969",
publisher = "Wichtig Publishing",
number = "1",

}

TY - JOUR

T1 - Analogs of luteinizing Hormone-Releasing hormone in the treatment of endometriosis

AU - Engel, Jörg B.

AU - Tinneberg, Hans R.

AU - Block, Norman L

AU - Berkes, Eniko

AU - Schally, Andrew V

PY - 2015/4/10

Y1 - 2015/4/10

N2 - Agonists of luteinizing hormone-releasing hormone (LHRH) induce a reversible hypoestrogenic state through the down-regulation of LHRH receptors and desensitization of the pituitary. Since endometrial implants are estrogen sensitive, LHRH agonists have frequently been used for medical treatment of endometriosis. Nowadays, LHRH agonists can be considered in general as a second-line medical treatment for endometriosis-related symptoms, as oral therapy with dienogest is as effective and has fewer side effects. However, therapy with LHRH agonists for 3-6 months prior to in vitro fertilization remains the treatment of choice in patients with endometriosis, as it significantly increases pregnancy rates. LHRH agonists are used prior to surgery and as an adjuvant after an operation to prevent recurrence or prolong disease-free intervals. Adverse effects of LHRH agonists are due to hypoestrogenism and include hot flushes, vaginal dryness, loss of libido, sleep disturbances and a diminished bone density which limits the duration of their administration to 6 months. For long-term treatment, add-back of estrogen and/or progestin,/or progestin only with or without bisphosphonates, can be used, but existing studies only cover a 12-month period of treatment. LHRH antagonists competitively block the pituitary receptors for LHRH. Consequently, a partial pharmacological hypophysectomy with a reduction of the estrogen levels to a desired level is possible if LHRH antagonists are adequately dosed. As endometriotic implants require relatively high levels of estrogen, partially lower plasma levels of estrogens are sufficient to prevent the loss of bone density. A long-term treatment without add-back therapy is also possible.

AB - Agonists of luteinizing hormone-releasing hormone (LHRH) induce a reversible hypoestrogenic state through the down-regulation of LHRH receptors and desensitization of the pituitary. Since endometrial implants are estrogen sensitive, LHRH agonists have frequently been used for medical treatment of endometriosis. Nowadays, LHRH agonists can be considered in general as a second-line medical treatment for endometriosis-related symptoms, as oral therapy with dienogest is as effective and has fewer side effects. However, therapy with LHRH agonists for 3-6 months prior to in vitro fertilization remains the treatment of choice in patients with endometriosis, as it significantly increases pregnancy rates. LHRH agonists are used prior to surgery and as an adjuvant after an operation to prevent recurrence or prolong disease-free intervals. Adverse effects of LHRH agonists are due to hypoestrogenism and include hot flushes, vaginal dryness, loss of libido, sleep disturbances and a diminished bone density which limits the duration of their administration to 6 months. For long-term treatment, add-back of estrogen and/or progestin,/or progestin only with or without bisphosphonates, can be used, but existing studies only cover a 12-month period of treatment. LHRH antagonists competitively block the pituitary receptors for LHRH. Consequently, a partial pharmacological hypophysectomy with a reduction of the estrogen levels to a desired level is possible if LHRH antagonists are adequately dosed. As endometriotic implants require relatively high levels of estrogen, partially lower plasma levels of estrogens are sufficient to prevent the loss of bone density. A long-term treatment without add-back therapy is also possible.

KW - Endometriosis

KW - LHRH agonist

KW - LHRH antagonist

KW - Medical treatment

UR - http://www.scopus.com/inward/record.url?scp=84928154710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928154710&partnerID=8YFLogxK

U2 - 10.5301/je.5000208

DO - 10.5301/je.5000208

M3 - Article

AN - SCOPUS:84928154710

VL - 7

SP - 19

EP - 26

JO - Journal of Endometriosis

JF - Journal of Endometriosis

SN - 2035-9969

IS - 1

ER -